Bellicum Pharmaceuticals (FRA:BPXA) Other Long-Term Liabilities : €29.63 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Other Long-Term Liabilities?

Bellicum Pharmaceuticals's other long-term liabilities for the quarter that ended in Sep. 2023 was €29.63 Mil.

Bellicum Pharmaceuticals's quarterly other long-term liabilities increased from Mar. 2023 (€21.08 Mil) to Jun. 2023 (€25.01 Mil) and increased from Jun. 2023 (€25.01 Mil) to Sep. 2023 (€29.63 Mil).

Bellicum Pharmaceuticals's annual other long-term liabilities increased from Dec. 2020 (€14.83 Mil) to Dec. 2021 (€15.96 Mil) and increased from Dec. 2021 (€15.96 Mil) to Dec. 2022 (€17.03 Mil).

Bellicum Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Bellicum Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Other Long-Term Liabilities Chart

Bellicum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long-Term Liabilities

Get a 7-Day Free Trial

Bellicum Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Bellicum Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Bellicum Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellicum Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals Headlines

No Headlines